Abstract
Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates. In the present study, the regional expression and activity of Bcrp and sulfotransferases (SULTs/Sults) were investigated in mouse intestine. Western blotting analysis revealed the highest expression of Bcrp in the ileum over the duodenum, jejunum, and colon. Functional analysis of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU). The mucosal secretion clearance of 4MU sulfate formed in the enterocytes was markedly reduced in the jejunum, ileum, and colon of Bcrp (-/-) mice in comparison with wild-type mice, whereas a slight and nonsignificant reduction was observed in the duodenum. The reduction in the mucosal secretion clearance was most marked in the ileum followed by the colon and jejunum. In addition, the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice. The sulfation activity of 4MU was higher in the colon than in the small intestine where glucuronidation activity was somewhat higher than the sulfation activity. Real-time polymerase chain reaction analysis showed that the expression of sulfotransferases, such as Sult1a1/2, Sult1b1, and Sult1d1, was also highest in the colon. These results suggest that Bcrp activity is higher in the mid to lower intestine and that the cooperation of Bcrp and SULT provides an important detoxification pathway, particularly in the colon.
Footnotes
-
doi:10.1124/dmd.106.011239.
-
This study was supported by a Grant-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science (KAKENHI 17209005).
-
ABBREVIATIONS: UGT, UDP-glucuronosyltransferase; SULT/Sult, sulfotransferase; ABC, ATP-binding cassette; P-gp, P-glycoprotein; MRP2, multidrug resistance-associated protein 2; BCRP/Bcrp, breast cancer resistance protein; ME3277, sodium hydrogen {4-[(4,5,6,7-tetrahydrothieno{3,2-c}pyridin-2-yl)carbonylamino]acetyl-o-phenylene} dioxydiacetate; MNXS, minoxidil sulfate; MNX, minoxidil; 4MUS, 4-methylumbelliferone sulfate; 4MUG, 4-methylumbelliferone glucuronide; 4MU, 4-methylumbelliferone; PBS, phosphate buffered saline; KRB, Krebs-Ringer buffer; LC, liquid chromatography; MS, mass spectrometry. SN-38, 7-ethyl-10-hydroxycamptothecin; E3040, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole.
- Received May 31, 2006.
- Accepted February 16, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|